Anthropic is no longer content being just a "contract IT guy" for Big Pharma. At the *The Briefing: AI for Science* event, Erik Kauderer-Abrams’ team unveiled Claude Science—an integrated workspace designed specifically for scientists. This move represents a bid to consolidate fragmented data and tools into a single ecosystem. While market leaders like AstraZeneca and Novo Nordisk currently treat AI as a supporting tool, Anthropic is building a full-scale research pipeline. By integrating scientific graphics and visualizations, Claude Science aims for the heart of the R&D process, pivoting from an API provider to the primary lab manager.
Seizing the Scientific Workflow
The real story here isn't about interface convenience; it's about aggressive vertical integration. Kauderer-Abrams, who leads Life Sciences at Anthropic, promises a "radical acceleration" of drug development. In practice, however, this creates an infrastructure trap: when the cycle from hypothesis to verification is locked inside Claude Science, the AI lab effectively privatizes the workflow. For competitors, entering such an ecosystem becomes prohibitively expensive. In our view, this is a classic maneuver to establish a new industry standard controlled by a single corporation.
Anthropic is openly positioning itself to develop its own drugs.
This ambition puts the company in an ambiguous and, frankly, predatory position. Anthropic is selling software to the very pharma giants it plans to compete with directly. It is the most aggressive attempt yet by a frontier AI lab to capture the margins of the final product—the drug itself—rather than settling for the crumbs of cloud-access licensing fees.
The Economics of "Forgotten Diseases"
Anthropic has chosen socially significant but commercially "neglected" diseases as a testing ground for its autonomous R&D. Strategically, this is a flawless move: in niches with low competition and high regulatory favor, it is easier to prove the power of generative search across chemical spaces. Professor Matthew Todd of University College London confirms that AI has already permeated modern science; however, Anthropic remains tight-lipped about the details. We currently know nothing of their specific targets or clinical trial roadmaps.
Reality vs. Autonomous Discovery
Despite the hype surrounding the "pharmacy boom," the distance between a molecule drawn by Claude and a bottle on a pharmacy shelf remains vast. Models can still hallucinate toxicity or overlook side effects, and testing hypotheses still requires physical test tubes, animal subjects, and the physical infrastructure that Anthropic lacks. Namshik Han from Cambridge rightly notes that AI is needed at every stage—from synthesis to manufacturing—but Anthropic has yet to explain how it will resolve conflicts of interest with its existing biotech clients.
The laboratory of the future is ready to generate perfect formulas, but it hasn't decided where to put the test tube racks. It appears that R&D departments risk becoming mere appendages to AI platforms, trading control over intellectual property for speed. Anthropic offers scientists a "convenient workflow," but the price of that convenience is the total loss of sovereignty over the process of discovery.